Renaissance Technologies LLC Boosts Stake in Tenaya Therapeutics, Inc. $TNYA

Renaissance Technologies LLC lifted its holdings in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 100.6% during the first quarter, Holdings Channel reports. The fund owned 3,713,761 shares of the company’s stock after purchasing an additional 1,862,894 shares during the quarter. Renaissance Technologies LLC’s holdings in Tenaya Therapeutics were worth $2,571,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Scientech Research LLC purchased a new stake in Tenaya Therapeutics during the 3rd quarter worth approximately $27,000. Integrity Wealth Solutions LLC acquired a new stake in Tenaya Therapeutics during the first quarter valued at approximately $27,000. Jefferies Financial Group Inc. acquired a new stake in shares of Tenaya Therapeutics during the 3rd quarter valued at approximately $99,000. Comerica Bank bought a new stake in Tenaya Therapeutics during the first quarter valued at $50,000. Finally, Corient Private Wealth LLC bought a new stake in Tenaya Therapeutics during the fourth quarter valued at $72,000. Hedge funds and other institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Stock Performance

TNYA opened at $0.73 on Monday. The business’s 50 day moving average is $0.77 and its 200-day moving average is $0.76. The stock has a market cap of $157.72 million, a PE ratio of -1.37 and a beta of 2.83. Tenaya Therapeutics, Inc. has a twelve month low of $0.53 and a twelve month high of $2.35.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.13). The business had revenue of $1.11 million during the quarter, compared to the consensus estimate of $10.00 million. As a group, analysts forecast that Tenaya Therapeutics, Inc. will post -0.4 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on TNYA. Wall Street Zen downgraded shares of Tenaya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Weiss Ratings raised shares of Tenaya Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Tenaya Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $4.00.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.